STANDARD BIOTOOLS INC. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 28/100
What the filing says
Standard BioTools Inc. agreed to sell its mass cytometry business (CyTOF, Hyperion platforms, Maxpar reagents) to Element Biosystems LLC for $5.5M base cash plus working capital adjustments. The deal includes share and asset transfers, assumption of business liabilities, and a $1M termination fee (paid by Buyer to Multiplex on behalf of Seller). Closing subject to stockholder approval and standard conditions.
Why this rating
Asset sale for $5.5M is ~1.9% of company market cap (~$291M). Divestiture reduces scope but preserves microfluidics business. Material but not transformational.
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.